Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 11/20 | 0.64 |
| ▸ | MELK | Q14680 | 1/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 7/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28977171 | 0.92 | MAP4K1 (0.66) | MAP4K1MELKPRKD1LCKMAP4K3 | |
| SCHEMBL28903809 | 0.90 | MELK (0.70) | MAP4K1MELKPRKD1 | |
| SCHEMBL28903830 | 0.90 | MAP4K1 (0.52) | MAP4K1MELKPRKD1FGFR1 | |
| SCHEMBL28960285 | 0.89 | MELK (0.57) | MAP4K1MELKPRKD1 | |
| SCHEMBL28960287 | 0.88 | MELK (0.60) | MAP4K1MELKPRKD1LCKMAP4K3 | |
| SCHEMBL19951647 | 0.88 | MELK (0.57) | MAP4K1MELKPRKD1LCKMAP4K3 | |
| SCHEMBL28903756 | 0.86 | MELK (0.64) | MAP4K1MELKPRKD1 | |
| SCHEMBL19951714 | 0.86 | MAP4K1 (0.48) | MAP4K1MELKFGFR1 | |
| SCHEMBL28903817 | 0.85 | MELK (0.63) | MAP4K1MELKPRKD1 | |
| SCHEMBL19951736 | 0.84 | MAP4K1 (0.54) | MAP4K1MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-109923114-B | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2022-11-01 | — | — | CN | disclosed |